Testing effectiveness (Phase 2)Looking for participantsNCT03667170What this trial is testingKN035 for dMMR/MSI-H Advanced Solid TumorsWho this might be right forSolid Tumor 3D Medicines (Sichuan) Co., Ltd. 200
Testing effectiveness (Phase 2)WithdrawnNCT04001101What this trial is testingAnti-PD-1 +/- RT for MSI-H Solid TumorsWho this might be right forMicrosatellite Instability HighMismatch Repair DeficiencyColorectal Cancer University of Colorado, Denver
Testing effectiveness (Phase 2)Active Not RecruitingNCT07523763What this trial is testingNeoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerWho this might be right forColorectal Cancer (MSI-H)Colorectal Cancer (CRC) Blokhin's Russian Cancer Research Center 30
Testing effectiveness (Phase 2)UnknownNCT04866862What this trial is testingFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal CancerWho this might be right forColorectal Neoplasm The First Affiliated Hospital with Nanjing Medical University 32
Early research (Phase 1)Ended earlyNCT05909995What this trial is testingInterventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsWho this might be right forMelanomaHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)+3 more Incyte Corporation 8
Large-scale testing (Phase 3)Active Not RecruitingNCT02997228What this trial is testingTesting the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT StudyWho this might be right forMetastatic Colorectal AdenocarcinomaStage IV Colorectal Cancer AJCC v7 National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT07160647What this trial is testingThe Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)Who this might be right fordMMR/MSI-H-type Rectal Adenocarcinoma Sir Run Run Shaw Hospital 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT04895722What this trial is testingEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)Who this might be right forColorectal Cancer Merck Sharp & Dohme LLC 302
Not applicableLooking for participantsNCT06477991What this trial is testingThe Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.Who this might be right forClinical Complete Response Rate With Negative MRD Yunnan Cancer Hospital 22
Testing effectiveness (Phase 2)UnknownNCT03638297What this trial is testingPD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal CancerWho this might be right forColorectal Cancer Sun Yat-sen University 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05841134What this trial is testingTislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal CancerWho this might be right forMSI-H Colorectal CancerTislelizumabOxaliplatin+1 more The First Affiliated Hospital of Zhengzhou University 25
Testing effectiveness (Phase 2)UnknownNCT03475953What this trial is testingA Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsWho this might be right forColorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more Institut Bergonié 747
Not applicableLooking for participantsNCT06353854What this trial is testingProspective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)Who this might be right forColorectal Cancer MetastaticMicrosatellite Instability-High Colorectal Cancer Federation Francophone de Cancerologie Digestive 600
Early research (Phase 1)Ended earlyNCT04458259What this trial is testingStudy of PF-07265807 in Participants With Metastatic Solid Tumors.Who this might be right forNeoplasm Metastasis Pfizer 88
Early research (Phase 1)Looking for participantsNCT06974110What this trial is testingStudy of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid TumorsWho this might be right forAdvanced Solid TumorMetastatic Solid TumorEndometrial Cancer+4 more MOMA Therapeutics 132
Large-scale testing (Phase 3)Study completedNCT02563002What this trial is testingStudy of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)Who this might be right forColorectal Carcinoma Merck Sharp & Dohme LLC 307
Testing effectiveness (Phase 2)Looking for participantsNCT07003022What this trial is testingPhase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRCWho this might be right forColo-rectal CancerMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Fudan University 40
Not applicableStudy completedNCT06414304What this trial is testingDynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor TherapyWho this might be right forColorectal CancerColorectal Cancer MetastaticMSI-H Colorectal Cancer+3 more OncoAtlas LLC 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05217446What this trial is testingEncorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Pfizer 107
Testing effectiveness (Phase 2)Looking for participantsNCT06903858What this trial is testingToripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal CancerWho this might be right forColorectal CancerMicrosatellite Instability HighMismatch Repair Deficiency Sun Yat-sen University 105